touchFEATURE Disease burden and unmet needs of patients with gastroenteropancreatic neuroendocrine tumours (GEP-NET)
Watch to learn more about the impact of GEP-NET on patients, and the need for earlier diagnosis.
Patient experience and unmet needs in the management of GEP-NET
Dr Rocío García-Carbonero, Head of GI Neuroendocrine Tumours Unit at Hospital Universitario 12 de Octubre, Madrid, Spain, discusses the results of patient surveys, which reveal the substantial impact of GEP-NET on patients’ personal and working lives.1,2 These surveys highlight unmet needs for earlier diagnosis and better access to NET specialist centres.1,21/2 Next Chapter
Importance of early diagnosis for patients with GEP-NET
Dr Christos Toumpanakis, Consultant in Gastroenterology & Neuroendocrine Tumours at the Royal Free Hospital, London, UK, discusses the benefits of early diagnosis of GEP-NET3,4 and provides recommendations for improving symptom awareness and early detection.2/2 Leave Feedback
Learning Objectives & Overview
Many patients with neuroendocrine tumours (NET), including gastroenteropancreatic NET (GEP-NET), experience delayed diagnosis,1-3 which is associated with stress and burnout – psychological symptoms that can compromise quality of life.3 More advanced (e.g. unresectable or metastatic) disease at diagnosis may result in reduced therapeutic options and worse survival outcomes.4,5
After watching this activity, participants should be better able to:
- Recognise the potential impact of GEP-NET on patients’ personal and working lives1,2
- Recall key unmet needs for patients with GEP-NET1,2
- Understand the importance of early diagnosis for patients with GEP-NET2,3
- Singh S, Granberg D, Wolin E, et al. Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From the First Global Survey of Patients With NETs. J Glob Oncol. 2016;3(1):43-53.
- Wolin EM, Leyden J, Goldstein G, et al. Patient-Reported Experience of Diagnosis, Management, and Burden of Neuroendocrine Tumors: Results From a Large Patient Survey in the United States. Pancreas. 2017;46(5):639-647.
- Keizer AC, Korse TCM, Meijer WG, Tesselaan MET. The effect of delay in diagnosis in patients with neuroendocrine tumors. Int J Endocrine Oncol. 2016;3:33-39.
- Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel). 2022;14(8):2028.
- Kos-Kudła B, Ćwikła J, Ruchała M, et al. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide. Contemp Oncol (Pozn). 2017;21(2):115-122.